ANN ARBOR, Mich. — A study led by the University of Michigan Cardiovascular Center shows being a woman may not increase your risk of dying from treatment for a severe heart attack.
U-M researchers and colleagues in the Michigan Cardiovascular Co…
Cardiologists at the University of Connecticut Health Center have identified a protein fragment that when detected in the blood can be a predictor of heart attack.
Their research, led by Dr. Bruce Liang, director of the Pat and Jim Calhoun C…
CINCINNATI — Helicopter emergency medical services can be a life saver for patients needing immediate care. But, according to a University of Cincinnati study, the process of activating them often delays treatment beyond recommended times.
The st…
ROCHESTER, Minn. – A team of Mayo Clinic researchers has found that patients with broken heart syndrome, also known as apical ballooning syndrome (ABS), have blood vessels that don’t react normally to stress. These results offer clues to the cause of…
The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile fo…
New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.
Dr Robert Storey, Reader at the University of Sheffield and Consultant Cardiologist a…
Researchers at The University of Western Ontario have provided the first direct evidence using a biological marker, to show chronic stress plays an important role in heart attacks. Stressors such as job, marital and financial problems have been lin…
NORFOLK, VA — Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection o…
A drug that blocks a heart-harming hormone can significantly reduce the risk of death and hospitalization in heart attack patients who have heart failure, with minimal side effects, a new international study released today shows. The life-saving effect began soon after patients begin taking the drug, called eplerenone, following their heart attacks. The effect was especially strong if patients were also on other heart medications, according to the results of the randomized, double-blind, placebo-controlled study of 6,632 patients in 37 countries.
Elderly heart attack patients who visit a cardiologist’s office in the months after leaving the hospital are less likely to die within two years than patients who visit only their primary care doctor, a study by Harvard Medical School researchers finds. And patients who visit both a cardiologist and a primary care doctor have even better outcomes than those who visit only a cardiologist.
In a sub-analysis of data from an earlier trial comparing the ability of three agents used to restore blood flow to patients soon after heart attacks, researchers have found that drugs used to prevent blood coagulation appear to have different effects in heart patients with diabetes. These findings, coupled with an assessment of ease of administration and cost compared to other drugs, has lead researchers to recommend the drug enoxaparin, which is a low-molecular weight heparin, for acute heart attack patients with diabetes.
By taking continuous electrocardiogram (ECG) readings for 24 hours after treating heart attack patients, researches have shown that giving a combination of a new drug that prevents platelets from clumping together, as well as a clot-busting drug, opens up clogged arteries faster and keeps them open longer.